Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

FDA Lab Test Oversight at Risk of Getting Cut From Year-End Bill

Nov. 18, 2022, 6:08 PM

Changes to how the Food and Drug Administration regulates diagnostic tests and other agency fixes could wind up on the chopping block as lawmakers seek compromise on measures to attach to an end-of-year spending package.

House and Senate negotiators are considering adding to a December omnibus bill provisions that were dropped earlier this year from a package (Public Law 117-180) reauthorizing industry user fees to the FDA. They’re preparing policy riders narrower than previous agreements, aides familiar with the discussions say, likely jettisoning more controversial provisions such as the VALID Act, which would allow the FDA to oversee ...